Evolution in the landscape of non-clinical safety testing for advanced therapies

Abi Pinchbeck, Assistant Editor, Cell & Gene Therapy Insights, speaks to Michaela Sharpe, Senior Nonclinical Director at Moare Solutions Ltd, about the evolving regulatory guidance surrounding non-clinical safety assessments for cell and gene therapies, as well as enabling the transition into the clinic and beyond.

Please enter your email to access content Read now